Beijing SL Pharmaceutical Co Ltd (002038) — Working Capital to Net Assets Ratio

Latest as of March 2026: 28.3%

Beijing SL Pharmaceutical Co Ltd (002038) has a Working Capital to Net Assets ratio of 28.3% as of March 2026. Working capital of CN¥1.44 Billion (current assets of CN¥2.05 Billion minus current liabilities of CN¥605.36 Million) is measured against net assets of CN¥5.10 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Beijing SL Pharmaceutical Co Ltd (002038) net asset quality to measure how much of total assets are equity-financed.

WC/NA Ratio

28.3%
Working Capital / Net Assets

Working Capital

CN¥1.44 Billion
CNY

Current Assets

CN¥2.05 Billion
CNY

Current Liabilities

CN¥605.36 Million
CNY

Beijing SL Pharmaceutical Co Ltd Working Capital to Net Assets (2001–2025)

This chart shows how Beijing SL Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 25 annual periods from 2001 to 2025. As of March 2026, the ratio stands at 28.3%, reflecting working capital of CN¥1.44 Billion against net assets of CN¥5.10 Billion CNY. Check tangible equity quality of Beijing SL Pharmaceutical Co Ltd to evaluate the tangible quality of the company's equity base.

Annual Working Capital to Net Assets for Beijing SL Pharmaceutical Co Ltd (2001–2025)

The table below presents the year-by-year Working Capital to Net Assets ratio for Beijing SL Pharmaceutical Co Ltd from 2001 to 2025, covering 25 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Beijing SL Pharmaceutical Co Ltd market capitalisation.

Year WC/NA Ratio Working Capital (CNY) Net Assets Current Assets Current Liabilities Change (pp)
2025 26.3% CN¥1.36 Billion CN¥5.19 Billion CN¥2.09 Billion CN¥729.59 Million ▼ -13.1 pp
2024 39.4% CN¥2.20 Billion CN¥5.58 Billion CN¥2.49 Billion CN¥289.41 Million ▲ +0.4 pp
2023 39.0% CN¥2.27 Billion CN¥5.81 Billion CN¥2.64 Billion CN¥373.33 Million ▲ +7.8 pp
2022 31.2% CN¥1.71 Billion CN¥5.48 Billion CN¥2.00 Billion CN¥288.83 Million ▼ -5.9 pp
2021 37.0% CN¥1.97 Billion CN¥5.33 Billion CN¥2.30 Billion CN¥324.96 Million ▼ -0.9 pp
2020 38.0% CN¥1.89 Billion CN¥4.98 Billion CN¥2.21 Billion CN¥314.98 Million ▼ -14.6 pp
2019 52.5% CN¥2.53 Billion CN¥4.82 Billion CN¥2.87 Billion CN¥332.63 Million ▲ +0.2 pp
2018 52.3% CN¥2.36 Billion CN¥4.52 Billion CN¥2.80 Billion CN¥440.52 Million ▼ -12.9 pp
2017 65.2% CN¥2.80 Billion CN¥4.30 Billion CN¥3.05 Billion CN¥249.67 Million ▼ -1.6 pp
2016 66.8% CN¥2.62 Billion CN¥3.93 Billion CN¥2.74 Billion CN¥113.67 Million ▼ -1.7 pp
2015 68.4% CN¥2.47 Billion CN¥3.61 Billion CN¥2.58 Billion CN¥111.00 Million ▲ +0.3 pp
2014 68.1% CN¥2.17 Billion CN¥3.18 Billion CN¥2.28 Billion CN¥115.74 Million ▲ +5.5 pp
2013 62.7% CN¥1.62 Billion CN¥2.59 Billion CN¥1.73 Billion CN¥103.52 Million ▼ -3.8 pp
2012 66.5% CN¥1.40 Billion CN¥2.11 Billion CN¥1.50 Billion CN¥92.22 Million ▼ -1.4 pp
2011 67.9% CN¥1.14 Billion CN¥1.69 Billion CN¥1.19 Billion CN¥45.22 Million ▲ +7.8 pp
2010 60.1% CN¥728.06 Million CN¥1.21 Billion CN¥765.29 Million CN¥37.22 Million ▼ -13.8 pp
2009 73.9% CN¥726.71 Million CN¥983.06 Million CN¥758.92 Million CN¥32.21 Million ▼ -6.1 pp
2008 80.1% CN¥610.60 Million CN¥762.61 Million CN¥636.50 Million CN¥25.91 Million ▲ +5.1 pp
2007 75.0% CN¥413.84 Million CN¥551.93 Million CN¥446.05 Million CN¥32.21 Million ▼ -0.3 pp
2006 75.3% CN¥320.77 Million CN¥426.20 Million CN¥346.82 Million CN¥26.05 Million ▲ +3.0 pp
2005 72.2% CN¥276.32 Million CN¥382.49 Million CN¥293.61 Million CN¥17.29 Million ▲ +0.0 pp
2004 72.2% CN¥260.96 Million CN¥361.45 Million CN¥283.24 Million CN¥22.28 Million ▲ +25.2 pp
2003 47.0% CN¥54.08 Million CN¥115.05 Million CN¥86.46 Million CN¥32.38 Million ▲ +7.9 pp
2002 39.1% CN¥33.51 Million CN¥85.61 Million CN¥45.16 Million CN¥11.65 Million ▼ -9.3 pp
2001 48.5% CN¥32.12 Million CN¥66.29 Million CN¥39.31 Million CN¥7.19 Million
pp = percentage points